They have developed a generic, so very little risk & definite market. Also the only generic of the world's best heparin.
Add the fact that they have a better manufacturing process than gsk, & gsk are interested in acl's process, & you have a beauty of a prospect.
All that said, I think it's better long term for holders if acl stay as they are. The partners are now carrying all the costs.
The other thing is that these partners are interested in other acl products. As well as acl's new drugs being developing, & the mtr products, you can be sure that acl will be working on other generics.
Expect full mtr takeover within the next two weeks. Also dow production news & milestone payment.
ACL Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
